Effectiveness of Blended and Unguided Delivery of Mindfulness-based Cognitive Therapy for Cancer Patients

Cancer Clinical Trial

— BUDDY  

Official title:

(Cost)Effectiveness of Blended and UnguideD DeliverY of Mindfulness-based Cognitive Therapy Versus Care as Usual for Cancer Patients: BUDDY Project

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05336916
• Other study ID #: NL73117.091.20
• Status: Recruiting
• Phase: N/A
• Start date: January 20, 2021
• Est. completion date: July 2023

Study information

• Verified date: March 2022
• Source: Radboud University Medical Center
• Contact: Anne EM Speckens, MD, PhD
• Phone: (024) 366 84 56
• Email: anne.speckens[@]radboudumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale: Approximately one in three cancer patients and survivors experience significant psychological distress. Previous research has shown that mindfulness-based interventions such as mindfulness-based cognitive therapy (MBCT) can help reduce distress among cancer patients. However, MBCT typically takes place in face-to-face group sessions, which are not easily accessible to many cancer patients. Blended therapist-assisted (combination of group sessions and individual online sessions) and unguided online MBCT interventions may address this problem, however, research on effectiveness of these interventions is missing.

Objective: This three-armed, randomized controlled trial (RCT) evaluates the effectiveness and cost-effectiveness of blended therapist-assisted (blended MBCT) and unguided individual internet-based MBCT (online MBCT) compared to treatment-as-usual (TAU) for cancer patients. Secondly, consolidation of treatment effects is studied up to nine months post-treatment. Thirdly, possible working mechanisms and effect moderators are studied.

Study design: The current study is a RCT with three arms (blended MBCT, online MBCT and TAU) with assessments at baseline (T0), mid-treatment, post-treatment (T1) and 3 months follow-up (T2). At 3 months follow-up (T2), patients in the TAU arm will be crossed over to blended MBCT or online MBCT (random allocation). Uncontrolled follow-up assessments will be conducted at 6 (T3) and 9 months (T4) follow-up.

Study population: 254 adults (>18 years) who have or have had a cancer diagnosis (any stage/any type) will be randomized.

Intervention: Patients will be randomly assigned with a 1:1:1 ratio to one of three groups:

(1) blended MBCT: patients will be invited to a blended therapist-assisted MBCT program, consisting of 8 weekly sessions (4 online group meetings, 4 online sessions with therapist assistance, and an online silent day), in addition to TAU; (2) online MBCT: patients will be invited to an individual internet-based MBCT program without assistance from a therapist, that consists of 8 weekly sessions and a silent day, in addition to TAU; (3) TAU: patients receive usual care, which can be medical, psychological or paramedical care, except mindfulness interventions.

Main study parameters/endpoints: Primary outcome is the difference in Hospital Anxiety and Depression Scale (HADS) total scores between patients in the blended MCBT and TAU arms and between the online MCBT and TAU arms post-treatment (T1).

Description:

About one in three cancer patients experience significant levels of psychological distress, requiring intervention from a health professional. Unfortunately, however, many cancer patients experiencing psychological symptoms do not receive treatment.

Effective psychological treatments for cancer patients are available. Evidence for the effectiveness of mindfulness-based interventions (MBIs) such as Mindfulness-based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) in oncology has rapidly increased. MBIs have beneficial effects on depression symptoms, anxiety, fear of cancer recurrence and fatigue. Also, preliminary results indicate that MBIs are cost-effective in cancer care.

However, there are known patient-reported barriers to engaging in face-to-face psychological interventions, such as investment of time, stigma, reluctance to return to the hospital, and indirect costs. In contrast, internet-based interventions are easily accessible and save travelling time. Evidence of over 100 trials suggests that internet-based treatments can be as effective as face-to-face treatments for psychiatric and somatic conditions. MBIs are also being delivered via Internet, but research on internet-based MBIs (eMBIs) has been mostly conducted in the general population.

Studies on the effectiveness of eMBIs in cancer patients are scarce. Our team conducted the first RCT comparing group MBCT and individual internet-based MBCT with TAU in patients with cancer. Therapist-assisted individual internet-based MBCT was similar to group MBCT in terms of treatment protocol, but took place individually and was guided one-on-one by a therapist on a weekly basis. Results indicated that both group MBCT and individual internet-based MBCT were significantly effective in reducing psychological distress in cancer patients compared to TAU. Moreover, both interventions significantly increased secondary quality-of-life outcomes with small to moderate effect sizes. Patients further improved over the course of the 9 months post-treatment, with patients who were less conscientious and less mindful at baseline benefitting more from therapist-assisted individual internet-based MBCT than group MBCT. Cost-effectiveness analyses demonstrated dominance of both interventions compared to TAU, indicating both higher quality of life and lower societal costs. In short, individual internet-based MBCT rendered MBCT much more accessible for cancer patients without compromising intervention efficacy or societal costs.

However, the proportion of patients receiving a lower dosage of MBCT than intended was substantially higher in individual internet-based MBCT than in group MBCT and although cost-effective, the individual internet-based MBCT proved to be resource intensive in terms of therapist assistance. Moreover, patients mentioned lack of peer support and the asynchronous communication with their therapist as important disadvantages of individual internet-based MBCT. Consequently, there is room to improve individual internet-based MBCT prior to implementation to ensure adherence and scalability.

To improve adherence and scalability, the investigators have developed two new versions of the effective online MBCT program with therapist assistance in a co-creation process together with relevant stakeholders. To improve adherence, a blended therapist-assisted MBCT (blended MBCT) was developed, combining four online group sessions with a therapist with four individual therapist-assisted online sessions. Furthermore, to improve scalability, unguided individual internet-based MBCT (online MBCT), which is similar to the previously studied individual internet-based MBCT protocol but without therapist guidance was also developed. As adherence to unguided interventions often is lower than intended, persuasive technology known to improve adherence was included, such as reminders and virtual coaches.

The current study primarily aims to investigate the effectiveness and cost-effectiveness of blended MBCT and online MBCT in comparison to treatment-as-usual (TAU) in a randomized controlled trial (RCT). Secondly, the aim is to test the consolidation of treatment effects up to nine months post-treatment. Thirdly, the investigators want to investigate working mechanisms and treatment effect moderators, to address how these programs work, and for whom.

The aim is to include 254 patients who were diagnosed with cancer (any stage, any tumor). After baseline assessment, patients will be randomized to the blended MBCT, unguided online MBCT or TAU (1:1:1 ratio). Outcome assessment for the RCT will occur at baseline (T0), immediately post-treatment (T1; primary endpoint) and three months follow-up (T2). Patients participating will also receive follow-up questionnaires at 6 months (T3) and 9 months (T4) post-treatment. At week 5 of both interventions (and at the same time during TAU), patients will be invited to complete a mid-treatment assessment, to look at working mechanisms. At 3 months follow-up (T2), patients in TAU will be randomized to the blended MBCT or unguided online MBCT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 254
• Est. completion date: July 2023
• Est. primary completion date: January 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. A cancer diagnosis, any tumor or stage

2. Computer literacy and internet access

3. Good command of the Dutch language

4. Willingness to participate in either MBCT intervention

Exclusion Criteria:

1. Previous participation in MBSR or MBCT (>4 sessions)

2. Severe psychiatric comorbidity that warrants acute treatment (psychosis, mania, severe personality disorders, suicidal thoughts)

3. Alcohol or drug dependence

4. Severe cognitive impairments

Related Conditions & MeSH terms

• Cancer

Intervention

Behavioral:
• Buddy
Mindfulness-based Cognitive Behavioural Therapy

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen	Gelderland

Sponsors (2)

Lead Sponsor	Collaborator
Radboud University Medical Center	Dutch Cancer Society

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in Hospital Anxiety and Depression Scale (HADS) total scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The HADS is a 14-item questionnaire measuring distress. Items are scored on a 0-3 scale that are summed to obtain a distress total score (range 0-42). Higher scores represent more distress.	1 week post-treatment
Secondary	Difference in Hospital Anxiety and Depression Scale (HADS) total scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The HADS is a 14-item questionnaire measuring distress. Items are scored on a 0-3 scale that are summed to obtain a distress total score (range 0-42). Higher scores represent more distress.	3, 6 and 9 months post-treatment
Secondary	Difference in Fear of Cancer Recurrence Inventory (FCRI) severity subscale scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The 9-item Fear of Cancer Recurrence Inventory severity subscale assesses fear of cancer recurrence on a 5-point Likert scale ranging from 0 (not at all or never) to 4 (a great deal or all the time). Higher scores indicate higher levels of FCR.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Checklist Individual Strength (CIS)- Fatigue scores between patients in the Blended MBCT arm and TAU, and between Online MBCT arm and TAU	The 8-item CIS-Fatigue Severity measures the patient's fatigue levels over the past 2 weeks on a 7-point scale, with higher scores indicating higher levels of fatigue.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Rumination and Reflection Questionnaire (RRQ) rumination subscales scores between patients in the Blended MBCT arm and TAU, and between Online MBCT arm and TAU	Rumination will be measured using the rumination 12-item subscale of the Rumination and Reflection Questionnaire. Items are scored on a five-point rating scale, with higher scores indicating more rumination.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Five Facet Mindfulness Questionnaire Short Form (FFMQ-SF) scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The 24-item Five Facet Mindfulness Questionnaire Short Form assesses mindfulness skills and consists of five subscales: observing, describing, acting with awareness, non-judging of inner experience and non-reactivity to inner experience. Items are scored on a five-point rating scale (1 = rarely true, 5 = always true). Higher scores are indicative of someone who is more mindful in their everyday life.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Decentering subscale of the Experiences Questionnaire scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The 11-item Decentering subscale of the Experiences Questionnaire measures the ability to observe one's thoughts and feelings as temporary, objective events in the mind. Participants rate items on a 5-point Likert scale (1 = never to 5 = always). Higher scores indicate greater decentering ability.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Self-Compassion Scale Short Form (SCS-SF) scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The Self-compassion Scale-Short Form is a 12-item self-report measure that is used to measure people's capacity for self-compassion. Items are scored on a five-point Likert scale (0 = 'Almost never' to 5 = 'Almost always') to record how often you behave kindly and caringly towards yourself in difficult life situations. Higher scores reflect higher levels of self-compassion.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in Mental Health Continuum-Short Form (MHCSF) scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The 14-item MHCSF measures positive mental health, consisting of three subscales: 1) emotional well-being, 2) psychological well-being, and 3) social well-being. Items assess the frequency with which respondents experience each symptom of positive mental health on a 6-point Likert scale ranging from 0 "never" to 5 "everyday" Higher scores indicate greater levels of positive well-being.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in EuroQol-5D-5L (EQ-5D) index scores between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The EQ-5D is a generic instrument comprising five domains with five levels: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D index is obtained by applying predetermined weights to the five domains. This index gives a societal-based global utility score of the participant's health status on a scale with 0 (death) and 1 (perfect health)	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Difference in the Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P) between patients in the Blended MBCT arm and TAU, and between patients in the Online MBCT arm and TAU	The Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P) will be used to collect information on direct healthcare use (e.g. general practitioner, mental healthcare and hospital day care visits) and paid and informal work-related productivity losses. Higher scores indicate greater healthcare use and productivity losses.	1 week post-treatment and 3, 6 and 12 months post-treatment
Secondary	Engagement with the intervention will be measured with Twente Engagement with Ehealth Technologies Scale (TWEETS) among participants in the blended and online MCBT arms	The TWEETS consists of 9 items, divided over 3 subscales: behavioural engagement, cognitive engagement and affective engagement. On a scale of 1 to 5, participants indicate the extent to which they agree with statements such as "I think I will be able to use this [technology] as often as needed [to achieve my goals]" (behavioural engagement), "this [technology] will motivate me to [goal of the technology]" (cognitive engagement) or " I think I will enjoy using this [technology]" (affective engagement).	1 week post-treatment